Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 219

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 219
---
 the credit line to $2,000,000. On March25, 2024, the parties entered into a fourth amendment to the Sponsor Loan Agreement, pursuant to which certain commercial conditions were amended, including the placement of a legend on 700,000 SPAC Ordinary Shares owned by the Sponsor and changes to the maturity date. The Sponsor Loan Agreement accrues interest at 11% per annum and matures either on the first, second or third anniversary of the closing of the Business Combination, according to certain thresholds related to the volume weighted average price of Company Shares on such dates. On November9, 2023, the rights and obligations of Mr. Bransfield under the Sponsor Loan Agreement were transferred to the Sponsor and the Sponsor assumed such rights and obligations. The Sponsor Loan accrues interest at 11% per annum and matures on February17, 2025. As of March31, 2025, $2,000,000 has been drawn under the Sponsor Loan Agreement, of which $1,743,499 has been lent onward from the Sponsor to APx under the Amended and Restated Note. If APx does not complete an initial business combination, it is unlikely that Sponsor will recover funds drawn by APx under the Amended and Restated Note and, as a result, such funds will not be available to repay amounts drawn under the Sponsor Loan Agreement; •the Sponsor is expected to hold an aggregate of approximately 9.5%, and the Initial Sponsor is expected to hold an aggregate of approximately 2.8%, of the outstanding Company Shares upon the consummation of the Business Combination, assuming no redemptions by Public Shareholders; •although there are no such unreimbursed out -of -pocketexpenses as of June30, 2024, unless a business combination is consummated, members of the APx Board will not receive reimbursement for any out -of -pocketexpenses incurred by them on APx’s behalf incident to identifying, investigating, negotiating and completing a business combination to the extent such expenses exceed the amount not required to be retained in the Trust Account; •the continuation of Kyle Bransfield, the chairman of the APx Board, as a director of the Company, and his appointment as chief financial officer of the Company, following the Closing; •the continued indemnification of APx’s current and former officers and directors and the continuation of directors’ and officers’ liability insurance after the Business Combination; •APx’s Existing Governing Documents provide that APx ren